Virax Biolabs Net Worth
Virax Biolabs Net Worth Breakdown | VRAX |
Virax Biolabs Net Worth Analysis
Virax Biolabs' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Virax Biolabs' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Virax Biolabs' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Virax Biolabs' net worth analysis. One common approach is to calculate Virax Biolabs' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Virax Biolabs' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Virax Biolabs' net worth. This approach calculates the present value of Virax Biolabs' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Virax Biolabs' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Virax Biolabs' net worth. This involves comparing Virax Biolabs' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Virax Biolabs' net worth relative to its peers.
To determine if Virax Biolabs is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Virax Biolabs' net worth research are outlined below:
| Virax Biolabs Group generated a negative expected return over the last 90 days | |
| Virax Biolabs Group has high historical volatility and very poor performance | |
| Virax Biolabs Group may become a speculative penny stock | |
| Virax Biolabs Group currently holds 224.3 K in liabilities. Virax Biolabs Group has a current ratio of 0.04, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Virax Biolabs' use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 156.42 K. Net Loss for the year was (6.74 M) with loss before overhead, payroll, taxes, and interest of (1.36 K). | |
| Virax Biolabs Group currently holds about 21.76 K in cash with (6.25 M) of positive cash flow from operations. | |
| Latest headline from simplywall.st: Virax Biolabs Group First Half 2025 Earnings US0.89 loss per share |
Virax Biolabs uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Virax Biolabs Group. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Virax Biolabs' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of September 2023 Upcoming Quarterly Report | View | |
| 30th of June 2023 Next Fiscal Quarter End | View | |
| 12th of June 2024 Next Fiscal Year End | View | |
| 31st of March 2023 Last Quarter Report | View | |
| 31st of March 2023 Last Financial Announcement | View |
Know Virax Biolabs' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Virax Biolabs is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Virax Biolabs Group backward and forwards among themselves. Virax Biolabs' institutional investor refers to the entity that pools money to purchase Virax Biolabs' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Renaissance Technologies Corp | 2024-09-30 | 145.4 K | Virtu Financial Llc | 2024-06-30 | 28.1 K | Hrt Financial Llc | 2024-06-30 | 25.7 K | Ubs Group Ag | 2024-06-30 | 5.6 K | Qube Research & Technologies | 2024-06-30 | 300 | Headlands Technologies Llc | 2024-09-30 | 185 | Wells Fargo & Co | 2024-06-30 | 100.0 | Citadel Advisors Llc | 2024-06-30 | 0.0 |
Follow Virax Biolabs' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 8.99 M.Market Cap |
|
Project Virax Biolabs' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.24) | (1.30) | |
| Return On Capital Employed | (1.22) | (1.16) | |
| Return On Assets | (1.23) | (1.29) | |
| Return On Equity | (1.25) | (1.19) |
When accessing Virax Biolabs' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Virax Biolabs' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Virax Biolabs' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Virax Biolabs' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Virax Biolabs Group. Check Virax Biolabs' Beneish M Score to see the likelihood of Virax Biolabs' management manipulating its earnings.
Evaluate Virax Biolabs' management efficiency
Virax Biolabs Group has return on total asset (ROA) of (0.499) % which means that it has lost $0.499 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9598) %, meaning that it created substantial loss on money invested by shareholders. Virax Biolabs' management efficiency ratios could be used to measure how well Virax Biolabs manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.3 in 2024. Return On Capital Employed is likely to rise to -1.16 in 2024. At this time, Virax Biolabs' Net Tangible Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 1.2 M in 2024, whereas Total Assets are likely to drop slightly above 3.4 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.56 | 1.30 | |
| Tangible Book Value Per Share | 2.54 | 1.27 | |
| Enterprise Value Over EBITDA | 0.29 | 0.30 | |
| Price Book Value Ratio | 0.27 | 0.29 | |
| Enterprise Value Multiple | 0.29 | 0.30 | |
| Price Fair Value | 0.27 | 0.29 | |
| Enterprise Value | -1.9 M | -2 M |
Evaluating the management effectiveness of Virax Biolabs allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Virax Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Enterprise Value Revenue 24.535 | Revenue 156.4 K | Quarterly Revenue Growth 27.522 | Revenue Per Share 0.078 | Return On Equity (0.96) |
Virax Biolabs Corporate Filings
6K | 20th of November 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
| 30th of September 2024 Other Reports | ViewVerify | |
| 20th of August 2024 Other Reports | ViewVerify |
Virax Biolabs Earnings per Share Projection vs Actual
Virax Biolabs Corporate Management
| Tomasz George | Chief Officer | Profile | |
| Joel Yeung | Accounting Manager | Profile | |
| Nigel MSc | Chief Officer | Profile | |
| Cameron Shaw | COO Director | Profile | |
| James Wang | Head Sourcing | Profile | |
| James Foster | Chairman CEO | Profile |
Additional Tools for Virax Stock Analysis
When running Virax Biolabs' price analysis, check to measure Virax Biolabs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virax Biolabs is operating at the current time. Most of Virax Biolabs' value examination focuses on studying past and present price action to predict the probability of Virax Biolabs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virax Biolabs' price. Additionally, you may evaluate how the addition of Virax Biolabs to your portfolios can decrease your overall portfolio volatility.